BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17709554)

  • 1. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
    Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
    J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
    Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
    Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.
    Haicheur N; Benchetrit F; Amessou M; Leclerc C; Falguières T; Fayolle C; Bismuth E; Fridman WH; Johannes L; Tartour E
    Int Immunol; 2003 Oct; 15(10):1161-71. PubMed ID: 13679386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
    Okazaki S; Iwasaki T; Yuba E; Watarai S
    J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
    Kim D; Hung CF; Wu TC; Park YM
    Vaccine; 2010 Oct; 28(45):7297-305. PubMed ID: 20817010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
    Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
    Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
    Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
    Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.
    Sasakawa A; Tatsumi T; Takehara T; Yamaguchi S; Yamamoto M; Ohkawa K; Miyagi T; Hayashi N
    J Hepatol; 2009 Jun; 50(6):1155-62. PubMed ID: 19376606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
    Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
    J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
    El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
    Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
    Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
    J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
    Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
    Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response.
    Liu Z; Lefrançois L
    J Immunol; 2004 Oct; 173(7):4324-30. PubMed ID: 15383561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
    Guillonneau C; Mintern JD; Hubert FX; Hurt AC; Besra GS; Porcelli S; Barr IG; Doherty PC; Godfrey DI; Turner SJ
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3330-5. PubMed ID: 19211791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation.
    Chung Y; Chang WS; Kim S; Kang CY
    Eur J Immunol; 2004 Sep; 34(9):2471-9. PubMed ID: 15307179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
    Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
    Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.